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There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive, negative, and cognitive symptoms of
schizophrenia. Building on recent studies with a racemic mixture of the synthetic tetrahydroprotoberberine, D,L-Govadine, we isolated the
D- and L-stereoisomers and employed a battery of behavioral, neurochemical, and electrophysiological procedures to assess their individual
therapeutic potential. Rodent models predictive of antipsychotic efficacy and those that model positive symptoms were employed and we
found that L-Govadine, but not D-Govadine, improved these measures. Pretreatment with either stereoisomer during CS pre-exposure
prevented the disruption of latent inhibition by amphetamine. Moreover, pretreatment with either stereoisomer also improved deficits in
social interaction in the neonatal ventral hippocampal lesioned rat. Improved cognitive performance in two different prefrontal cortex-
dependent tasks was observed with D-, but not L-Govadine, which strongly suggests that the D-steroisomer may be an effective cognitive
enhancer. Alterations in dopamine efflux were also assessed and L-Govadine increased dopamine efflux in both the prefrontal cortex and
nucleus accumbens. However, D-Govadine only increased dopamine efflux in the prefrontal cortex and not in the nucleus accumbens.
Electrophysiological studies confirmed that L-Govadine is a DA-D2 antagonist, whereas D-Govadine shows no appreciable physiological
effects at this receptor. Collectively these data show that L-Govadine performs well on measures predictive of antipsychotic efficacy and
rodent models of positive symptoms through antagonism of DA-D2 receptors, whereas D-Govadine improves impairments in
compromised memory function in delayed response tasks possibly through selective increases in DA efflux in the frontal cortex.
Neuropsychopharmacology (2014) 39, 1754–1762; doi:10.1038/npp.2014.23; published online 26 February 2014
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INTRODUCTION
The positive symptoms of schizophrenia respond well to
treatment with both typical and atypical antipsychotic drugs,
which is attributable to their shared property as dopamine
(DA) D2 antagonists (Kapur et al, 2006). Unfortunately,
drugs that effectively manage negative and cognitive
symptoms are still forthcoming. This is a particularly urgent
issue as impaired cognitive function is a core symptom of
schizophrenia (Andreasen, 2000; Freedman, 2003) and
improvements in this domain are particularly strong
predictors of positive treatment outcomes and social
reintegration (Hofer et al, 2011; Uggerby et al, 2011).
A growing body of preclinical evidence has focused
interest on tetrahydroprotoberberines (THPB), including
L-Stepholidine (L-SPD), in the treatment of schizophrenia
and Parkinson’s disease (Jin et al, 2002; Natesan et al, 2008).
L-SPD has a unique neuropharmacological profile as a D1
agonist and D2 antagonist (Dong et al, 1997). D1 receptors
have a critical role in modulating executive function in
the medial prefrontal cortex and D1 agonists have been
proposed as promising candidates for ameliorating cogni-
tive deficits associated with schizophrenia (Goldman-Rakic
et al, 2000, 2004). Recently, we reported that the racemic
THPB, D,L-Govadine (D,L-GOV), performed well on a
number of preclinical behavioral measures predictive of
efficacy in the treatment of positive and cognitive symp-
toms (Lapish et al, 2012). Of particular interest in these
previous studies was an increase in DA efflux in the PFC
evoked by D,L-GOV, along with improvements in a memory-
guided foraging task linked to optimal DA function in the
PFC (Seamans et al, 1998).
Subsequent to these initial experiments with D,L-GOV, a
chiral separation procedure was developed that yielded
the stereoisomers, D-Govadine (D-GOV) and L -Govadine
(L-GOV) (Zhai et al, 2012). Although stereoisomer-specific
formulations may have similar functional properties
(Ferrari et al, 1995), often each stereoisomer can display
distinct pharmacological properties (Bingham et al, 2007;
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Robaa et al, 2011). Stereo-specific formulations of drugs
with proven pharmacological efficacy can improve ther-
apeutic outcomes via reduced side effects and more
accurate dosing (Agranat and Caner, 1999; De Camp,
1989). As such, the FDA and EMEA have encouraged the
development of stereoisomer formulations (De Camp,
1989). The improved safety and efficacy conferred by
stereo-specific formulations, coupled with our preclinical
data indicating the possible efficacy of D,L-GOV on tests of
both positive symptoms and cognitive deficits, motivated a
comprehensive analysis of the behavioral, neurochemical,
and electrophysiological properties of D-GOV and L-GOV.
This report identifies unique, yet complementary, actions of
each isomer and provides compelling preclinical evidence
for their antipsychotic, prosocial, and possibly procognitive
properties.
MATERIALS AND METHODS
All procedures conformed to the guidelines outlined by the
Canadian Council on Animal Care and the National
Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the the
Institutional Animal Use and Care Committee at IUPUI.
All procedures were performed in male Long Evans rats
unless otherwise noted.
Receptor Binding
The affinity of D-GOV and L-GOV for DA, serotonin, and
noradrenaline receptors were assessed (see Supplementary
Information) by MDS Pharma Services (King of Prussia, PA).
Behavior
In depth descriptions of each behavioral task can be found
in the Supplementary Material.
Amphetamine-induced locomotion (AIL) was assessed
for 1 h in a dimly lit open field following administration of
an intraperitoneal injection of D-AMPH (1.5mg/kg). Fifteen
min before the D-AMPH injections, animals received
subcutaneous (SC) injections of vehicle, D-GOV, L-GOV,
or clozapine.
Catalepsy was assessed after a SC injection of vehicle, D-
GOV, or L-GOV. The cumulative time spent with forelimbs
immobilized on a horizontal bar was scored over a 2-min
period beginning 1, 15, 30, and 45min after injection.
Conditioned avoidance responding (CAR) was assessed
in animals that demonstrated proficiency in a two-way
avoidance Pavlovian conditioning paradigm, evidenced by
an association between the conditioned stimulus (CS; white
noise,B60 dB) and unconditioned stimulus (US; footshock,
0.75mA) that, with repeated pairing, led to an avoidance
response after presentation of the CS. One day after
demonstrating a clear association between the CS and US,
pharmacological testing occurred. On the test day animals
received SC injections of vehicle, D-GOV, L-GOV, or
clozapine 15min before CAR was assessed for 100 CS–US
pairings.
Latent inhibition (LI) experiments were designed to
examine whether treatment with either D-GOV or L-GOV
during the pre-exposure phase could suppress subsequent
D-AMPH-induced disruptions in LI. On the pre-exposure
days animals received injections of vehicle D-GOV (1.0mg/kg
SC) or L-GOV (1.0mg/kg SC). On the day of conditioning, LI
was assessed in a two-way avoidance Pavlovian conditioning
paradigm identical to the CAR procedure used. LI was
confirmed as a reduction in the number of avoidances
during the CAR test in animals pre-exposed to the CS
compared with those exposed to the CS for the first time.
This experiment also included treatment with D-AMPH
(1.0mg/kg) or saline vehicle, 45min before behavioral testing
to examine the effects of D-GOV or L-GOV during CS pre-
exposure on D-AMPH-induced disruption of LI. CAR
acquisition consisted of 100 CS–US pairings.
Social interaction (SI) was assessed in male Sprague
Dawley rats as described in (Truitt et al, 2009). Neonatal
ventral hippocampal lesioned (NVHL) and sham-lesioned
(Shams) rats were prepared as described in (Chambers et al,
2010). For detailed methods see Supplementary Inform-
ation. Briefly, on the day of SI testing, rats in both the
NVHL and Sham groups were injected with either vehicle
D-GOV (1.0mg/kg SC) or L-GOV (1.0mg/kg SC) 15min
before SI testing. The cumulative time spent by each rat
with its head oriented closely toward or in contact with the
conspecific animal was scored as SI.
Temporal order recognition memory was measured as the
preference of an animal to explore a location on an eight-
arm maze visited more remotely in time vs an arm visited
more recently and was performed as described in
(Hannesson et al, 2004). Briefly, 15min before the memory
test that took place either 60min or 240min after exploring
the second pair of arms, rats were injected with vehicle,
D-GOV (1.0mg/kg SC), L-GOV (1.0mg/kg SC), or clozapine
(5.0mg/kg SC). Time spent in each location (recent and
remote), total distance traveled, and the total number of
entries into each location were scored from video record-
ings off-line (see Supplementary Information).
Prospective working memory was assed by a spatial win-
shift task using a radial-arm maze (Seamans et al, 1998).
Rats were maintained at 85% target body weight and trained
to identify blocked arms that would subsequently contain
food after a delay period once food was obtained from six
open arms during the training phase. After a 1-min delay,
each rat was returned to the radial-arm maze with all eight
arms open. Memory for the correct arms, the two yet to be
visited that still contained food, was assessed to a criterion
of o2 errors on two consecutive days. After reaching
this criterion, animals were tested at a longer delay of
15min. Before these test trials, rats received counter-
balanced injections of vehicle, D-GOV (1.0mg/kg SC),
L-GOV (1.0mg/kg SC) 15min before the training phase.
Errors were scored as test-phase entries into arms visited
previously.
Microdialysis
Procedures were identical to those described in (Lapish et al,
2012), but see Supplementary Information. Once baseline
levels of DA efflux were stable, counterbalanced injections of
vehicle/D-GOV (1.0mg/kg SC) or vehicle/L-GOV (1.0mg/kg
SC) were administered. Microdialysis samples were collected
every 10min and analyzed immediately using high-pressure
liquid chromatography with electrochemical detection.
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Electrophysiology
To determine the effects of each isomer on ventral
tegmental area DA neuron firing, electrophysiological
experiments were performed in an acute slice preparation.
Briefly, male Sprague Dawley rats (3–5 weeks old) were
decapitated under halothane anesthesia and the brain was
rapidly removed and placed in ice-cold cutting solution.
Midbrain slices (220 mm) were prepared using a vibratome
and then incubated for 41 h at room temperature in
physiological saline. DA neurons were identified by
spontaneous pacemaker firing (1–3Hz) with broad APs
(X2.0ms) (Ahn et al, 2010). Cells not responding to
Quinpirole (500 nM) were excluded. Cells were also filled
with Alexa or Neurobiotin for post-hoc identification using
tyrosine hydroxylase immunostaining (see (Gorelova et al,
2012) for staining methods). Whole-cell voltage clamp
recordings (holding potential, Vh, set at  60mV)
were made using Sigma-coated pipettes with resistance of
5–7MO. All electrophysiological measurements were ob-
tained with an EPC-9 patch-clamp amplifier controlled by
Tida software (HEKA Electronik, Lambrecht, Germany).
All drugs including L- or D-Govadine (10 nM to 10 mM) were
bath-applied.
RESULTS
Receptor Binding
Both D-GOV and L-GOV exhibited higher affinity for DA-D1/
D5 receptors (o10 nM) as compared with DA-D2L receptors
(165 nM). Modest affinity for adrenergic receptors, and low
affinity for serotonin receptors was also observed (Figure 1a).
Amphetamine-Induced Locomotion
A dose-dependent attenuation of AIL was observed with
L-GOV treatment, but not D-GOV, even at a dose of 10.0mg/kg
(main effect of treatment, one-way ANOVA, F(11,65)¼ 25.47,
Po0.0001). Both doses of CLZ completely suppressed AIL to
levels that did not differ significantly from salineþVEH-
treated animals (Figure 1b).
Catalepsy
Catalepsy was induced in a dose-dependent manner by
L-GOV, but not D-GOV, (dose time interaction, two-way
ANOVA, F(20,149)¼ 10.64, Po0.0001, Figure 1c). Mini-
mum levels of catalepsy were observed with a dose of
1.0mg/kg L-GOV. Catalepsy peaked at 15min post treat-
ment with L-GOV (Figure 1c, inset).
Conditioned Avoidance Responding
A dose-dependent decrease in CAR was observed with
L-GOV but not D-GOV (main effect of treatment, one-way
ANOVA F(3,104)¼ 4.4, Po0.01). Pretreatment with CLZ
(5.0mg/kg) produced a small but significant decrease in
avoidance responses. Animals that exhibited a decreased
number of avoidances following drug treatment usually
escaped from the US (treatmentmeasure interaction, two-
way ANOVA, F(3,104)¼ 31.48, Po0.0001), confirming that
neither L-GOV nor CLZ treatment produced an overt motor
impairment at doses that disrupted CAR (Figure 1d).
Latent Inhibition
LI was assessed initially in rats treated with either saline or
1.0mg/kg D-AMPH on the test day (Figure 1e). Animals that
were given VEH before CS pre-exposure and then treated
with saline on the test day made significantly fewer
avoidance responses compared with the NPE group
receiving the same treatment, which is consistent with a
LI effect (main effect of CS-exposure, two-way ANOVA,
F(1,84)¼ 17.5, Po0.001). Rats treated with VEH during the
CS pre-exposure period and then given D-AMPH 1 h before
the CAR test, did not exhibit LI, thereby replicating the
commonly observed disruptive effect of a psychostimulant
on LI (Moser et al, 2000; Weiner et al, 2003). Treatment
with either L-GOV or D-GOV during CS pre-exposure
prevented disruption of LI in animals given D-AMPH before
conditioning (exposure treatment interaction, two-way
ANOVA, F(1,31)¼ 5.73, Po0.05; Figure 1e).
Social Interaction
Vehicle-treated rats in the NVHL group exhibited a marked
decrease in SI time (Bonferroni corrected planned compar-
ison, t(30)¼ 3.124, Po0.01; Figure 2). This effect was
reversed by treatment with either D-GOV or L-GOV, with
comparable levels of SI observed in NVHL and Sham
control groups.
Electrophysiology
Firing rates of confirmed DA neurons (Figure 3a), averaged
over the last 3min of a 10-min recording period were
suppressed by bath application of the D2 agonist Quinprole
and this effect was reversed by bath application of L-GOV,
but not D-GOV, (time treatment interaction, two-way
repeated measures ANOVA, F(2,6)¼ 15.238, Po0.001,
Figure 3b and c). The suppression of DA neuron firing
was mediated by G-coupled inward rectifying Kþ (GIRK)
channels, as bath application of the GIRK blocker, tertiapin,
blocked the quinprole-mediated increase in outward
currents (Figure 3d and e). The Quinprole effect was
unaltered by bath application of the GABAB antagonist,
Baclofen, indicating that GABAB currents were not involved
in the observed inhibition of firing in DA neurons
(Supplementary Figure 4).
Microdialysis
Peripheral administration of D-GOV increased DA efflux
in the PFC (treatment time interaction, two-way ANOVA,
F(18,228)¼ 1.71, Po0.05, Figure 4a) but not in the
NAc (treatment time interaction, two-way ANOVA,
F(18,209)¼ 0.14, P40.05, Figure 4b), relative to the VEH
condition. Increases in the efflux of DA metabolites were
also observed selectively in the PFC (Supplementary
Figures 2 and 3). L-GOV increased DA efflux in both
the PFC (treatment time interaction, two-way ANOVA,
F(18,228)¼ 1.87, Po0.05, Figure 4c) and in the NAc
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Figure 1 (a) Receptor-binding affinity (in nM) for dopamine, noradrenalin, and serotonin receptors. (b) Effects of D-GOV (light gray bars), L-GOV (dark
gray bars), or CLZ (white bars) on D-AMPH-induced locomotion (black bar). (c) Cataleptic effects of L-GOV but not D-GOV. (d) Effects of D-GOV (light
gray bars), L-GOV (dark gray bars), or CLZ (white bar) on CAR. (e) Treatment with either D-GOV or L-GOV before CS pre-exposure prevents disruption
of latent inhibition by D-AMPH but has no effect on CAR in saline-treated rats. *Po0.05, Tukey’s post-hoc test, comparison with salineþVEH group, (b);
*Po0.05, **Po0.01 comparison with VEH group (c and d); and *Po0.05, Tukey’s post-hoc test (e).
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Figure 2 (a) Photomicrographs from representative animals that received a neonatal ventral hippocampal lesion (NVHL) or a sham lesion (SHAM).
(b) Effects of D-GOV or L-GOV on social interaction time displayed by rats with NVHL (gray bars) or sham controls (black bars). *Po0.05, planned
comparison.
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depicting that L-GOV, but not D-GOV, reduced GIRK-mediated currents. ***Po0.001, Holm–Sidak (c) and Tukey’s (e) post-hoc test.
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(treatment time interaction, two-way ANOVA, F(18,209)¼
19.5, Po0.001, Figure 4d) relative to the VEH condition.
Temporal Order Recognition Memory (TORM)
VEH-treated rats displayed TORM in the present study by
spending more time in an arm visited in the first phase of
training, as compared with an arm visited in the second
phase of training 45min earlier (Figure 5a1). TORM was
disrupted in the VEH-control group by the imposition of a
240-min delay between the second phase of training and
the memory test (Figure 5a2). Treatment with either L-GOV
or CLZ disrupted TORM following the 45-min delay
(Figure 5a1) but had no effect on TORM after an extended
240-min delay (Figure 5a2). D-GOV given before a recall test
disrupted TORM after the 45-min delay, as rats in this
condition failed to show a preference for the arm visited
more remotely in time (Figure 5a1). In contrast, treatment
with D-GOV before a recall test after a 240-min delay
restored the preference for the arm visited more remotely in
time, consistent with restitution of TORM (D-GOV and VEH
groups, treatment delay arm interaction, factorial AN-
OVA, F(1,36)¼ 4.56, Po0.05). D-GOV treatment before the
45-min delay increased the distance traveled (main effect of
treatment, one-way ANOVA, F(3,42)¼ 29.87, Po0.001) and
the number of arm entries (main effect of treatment,
one-way ANOVA, F(3,42)¼ 12.47, Po0.01) during TORM
testing (Supplementary Table 1). When retested after a
240-min delay, rats treated with either L-GOV or CLZ moved
less and made fewer arm entries compared with the D-GOV
or VEH groups (Tukey’s post-hoc test, Po0.05), which is
consistent with the motor augmenting/sedative effects
typically observed with D2 antagonists (Fibiger et al,
1976). However, no significant differences were observed
in distance traveled or arm entries between D-GOV or VEH
groups after the 240-min delay (Tukey’s post-hoc test,
P40.05) ruling out changes in locomotor activity as
responsible for the restoration of TORM.
Delayed Win-Shift Following a 15-min Delay
Rats treated with D-GOV, but not L-GOV, displayed a
significant improvement in selection of arms that were
previously blocked during the training phase and baited
with food following a 15-min delay (Figure 5b). This was
reflected in a decrease in test-phase errors (Bonferroni
corrected planned comparison, D-GOV t(6)¼  3.873,
Po0.01; L-GOV t(6)¼ 0.8911, P40.05).
DISCUSSION
The present study confirms efficacy on preclinical tests of
positive symptoms of schizophrenia following treatment
with L-GOV and to a lesser extent with D-GOV, whereas the
improvement of impaired working memory and prospective
memory are a property of D-GOV. Impaired SI is typically
classified as a negative symptom and both isomers reversed
the impaired phenotype in the NVHL rat, a validated
preclinical model of schizophrenia (Tseng et al, 2009).
Collectively, these findings, in conjunction with our
previous work (Lapish et al, 2012), indicate that GOV in
both its racemic form and as separate isomers may have the
unique potential to address the three cardinal symptoms of
schizophrenia.
A comparison of the receptor-binding profiles of each
isomer reveals that both share a high affinity for the DA-D1/
D5 receptor family, whereas L-GOV has a much greater affinity
for the DA-DA2 receptor compared with D-GOV. Each isomer
also exhibits moderate affinity for noradrenaline receptors
and low affinity for 5-HT receptors (Figure 1a). In functional
binding assays reported previously, L-GOV reduces cAMP
formation (Lapish et al, 2012). Our electrophysiological data,
showing a complete reversal by L-GOV, but not D-GOV, of the
D2 autoreceptor-mediated inhibition of spontaneous firing
rates in identified DA neurons in VTA slices, are also consis-
tent with the classification of L-GOV as a DA-D2 antagonist.
The pharmacological profile of L-GOV is consistent with
previous studies outlining the DA-D2 antagonist action
of the THPB, L-Stepholidine (L-SPD; Dong et al, 1997).
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However, these data separate D-GOV and L-SPD on the basis
of actions at the DA-D2 receptor by showing that D-GOV
has low affinity and a behavioral profile inconsistent with
D2 antagonist effects. Functional binding studies have
established L-SPD to be a DA-D1 agonist (Natesan et al,
2008), however, no DA-D1 agonist activity could be detected
with D-GOV pointing to another possibly important
difference between these compounds.
As anticipated on the basis of the receptor-binding and
electrophysiological data, L-GOV displayed positive effects
on preclinical behavioral tests in rats predictive of
antipsychotic efficacy. Specifically, L-GOV suppressed CAR
and AIL in a dose-dependent manner (Figure 1b–d). Clear
differences were observed between the isomers in these two
classic tests of antipsychotic efficacy, as D-GOV had no
effect on either CAR or AIL (Figure 1b–d), consistent with
negligible binding or functional affinity at DA-D2 receptors
(Figure 1; Lapish et al, 2012).
Typical antipsychotics exert a stronger effect on DA efflux
in the ventral striatum than in the prefrontal cortex,
whereas comparable increases in DA efflux are observed
in both structures following treatment with atypical anti-
psychotics, including clozapine (Moghaddam and Bunney,
1990). Microdialysis experiments with D,L-GOV revealed a
pattern of DA efflux that is consistent with atypical
antipsychotics (Lapish et al, 2012). When this analysis is
extended to the individual isomers of GOV, two striking
patterns emerge. First, L-GOV similarly increased DA efflux
in both the PFC and ventral striatum, consistent with
atypical antipsychotic properties. Second, the effects of
D-GOV on DA efflux are restricted to the mPFC. The
mechanism for this unique ability to selectively enhance DA
effux in the frontal cortex remains to be specified, but could
lead to novel treatment strategies for hypodopaminergic
function within this region of the cortex.
In contrast to these clear differences between D- and
L-GOV, both isomers displayed similar effects on disruption
of LI by D-AMPH. Reversal of psychostimulant-induced
disruption of LI is interpreted as an analog of positive
symptoms of schizophrenia reflecting an inability to classify
environmental stimuli as irrelevant (Weiner and Feldon,
1997). In the present study, pretreatment with either isomer
before CS pre-exposure sessions prevented the subsequent
disruption of LI by D-AMPH (Figure 1e). Importantly,
treatment with D- or L-GOV during CS pre-exposure had no
effect on LI in the control group given saline before the
acquisition of CAR. These data replicate and extend our
previous findings with D,L-GOV (Lapish et al, 2012). The
fact that GOV, in both the racemic form or as separate
isomers, does not alter the expression of LI in saline-treated
animals, but prevents D-AMPH from disrupting LI suggests
that pretreatment with GOV may facilitate recall of the CS
on the day of conditioning. This effect could also reflect an
influence of GOV on sensory filtering, which is thought to
be impaired in schizophrenia (Bunney et al, 1999), and may
serve as an important predictor of antipsychotic efficacy.
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Figure 5 Effects of D-GOV (1.0mg/kg), L-GOV (1.0mg/kg), CLZ (5.0mg/kg), or VEH on (a1) TORM at a 45-min delay or (a2) 240-min delay. At the
45-min delay, TORM was expressed in the VEH group and treatment with D-GOV, L-GOV, or CLZ impaired TORM. At the 240-min delay VEH, L-GOV,
and CLZ groups did not exhibit TORM, but D-GOV restored TORM. (b) A decrease in test-phase errors of the delayed spatial win-shift was observed with
D-GOV but not L-GOV. *Po0.05, Tukey’s post-hoc test (a1 and a2) and *Po0.05, planned comparison b).
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The NVHL models many of the behavioral and biological
abnormalities observed in schizophrenia, and is regarded
as a valid neurodevelopmental model of this condition
(Tseng et al, 2009). Social withdrawal and isolation are the
commonly observed negative symptoms of schizophrenia
and are effectively modeled in the NVHL as deficits in SI
(Sams-Dodd et al, 1997). We find that pretreatment with
either isomer of GOV restored SI times to levels observed in
control animals (Figure 2) suggesting that negative symp-
toms may be treated effectively by either isomer of GOV.
This is also supported by our previous finding that
pretreatment with racemic GOV mitigates enhanced LI in
rats sensitized to d-AMPH (Lapish et al, 2012), which has
been proposed as a rodent model of negative symptoms
(Weiner and Arad, 2009).
Impairments in cognitive functions are hallmarks of
schizophrenia attributed, in part, to hypofunction of the
PFC DA system (Goldman-Rakic et al, 2004). Correct
identification of the temporal order in which events
occurred is impaired in schizophrenics (Dreher et al,
2001) and can be assessed in rats via their preference for
an object or location that was experienced more remotely in
time. The capacity to display TORM is dependent on the
integrity of the PFC and the DA system (Hannesson et al,
2004; Hotte et al, 2005). At the standard delay of 45min,
pretreatment with D-GOV disrupted TORM, consistent with
effects observed with a DA-D1 agonist in a test of delayed
win-shift responding (Floresco and Phillips, 2001). In
contrast, extension of the delay interval of the test from
the standard period of 45min to 240min, caused an
impairment in TORM that was rescued by pretreatment
with D-GOV before the recall test. Collectively, these data
show that D-GOV suppresses the expression of TORM under
conditions where the memory is expressed (45min), but
facilitates the recall of TORM when impaired (240-min
delay). This pattern closely resembles effects seen pre-
viously with DA-D1 agonists that impair working memory
performance under optimal conditions while improving
impaired performance in tasks dependent on the mPFC
(Seamans et al, 1998). Moreover, these data are consistent
with the hypothesis that optimal concentrations of DA are
essential for executive functions mediated by the mPFC, and
that these aspects of cognition are impaired when DA
fluctuates below or above these optimal values (Mattay et al,
2003; Phillips et al, 2004). Importantly, this explanation also
suggests that the elevation of DA efflux induced by D-GOV
may rescue impaired cognitive functions associated with
suboptimal DA functions, but suggests that D-GOV could
interfere with working memory or temporal order memory
function in situations where DA is functioning optimally.
Further evidence for beneficial effects of D-GOV on
impaired memory performance is provided by a reduction
of working memory errors in the delayed win-shift task.
Notably, L-GOV did not improve cognitive performance on
this task. These data are consistent with our previous
observation of improved recall with D,L-GOV under condi-
tions of impaired working memory (Lapish et al, 2012) and
further separate the effects of D-GOV from L-GOV with
respect to improvements in impaired memory function.
Although both D-GOV and L-GOV maintain high affinity
for the DA-D1 receptor, neither appear to act as a direct
agonist at this receptor (Figure 1a; Lapish et al, 2012).
Although the current study recommends further explora-
tion of D-GOV as a potential intervention to improve
impairments in cognitive function observed in schizophre-
nia, a number of pharmacotherapies that target the DA
system have not provided consistent improvement in
cognitive function in human subjects. D-GOV, however,
may provide a novel approach to targeting the DA system
given its unique ability to selectively increase DA efflux in
the PFC, but not in the NAc. Increases in PFC DA efflux, by
mechanisms yet to be specified, and not a direct action on
DA receptors, may explain the bidirectional effects observed
on TORM at short- and long-delay intervals and improved
radial-arm maze performance.
Pre-synaptic modulation of PFC DA efflux, as opposed to
a direct action on DA receptors, may explain the bidirec-
tional effects observed on TORM at short- and long-delay
intervals, and improved radial-arm maze performance.
COMT inhibitors maintain relative selectivity for the PFC
and hippocampal DA system via blocking the metabolism
and reuptake of DA in conjunction with a behavioral event
such as feeding or a pharmacological challenge (Lapish
et al, 2009; Tunbridge et al, 2004). Importantly, in the
current study treatment with D-GOV alone was sufficient
to increase DA efflux in the PFC, but not NAc, and to
our knowledge this is the first time a compound has
been identified with this profile. These data separate the
effects of D-GOV from L-GOV with respect to improvements
in impaired working memory and prospective memory and
recommend further investigation of its therapeutic potential
in the treatment of cognitive impairment associated with
schizophrenia and other neuropsychiatric disorders
(Goldman-Rakic et al, 2004).
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